文献速递妇科生殖医学

育龄期妇女子宫内膜癌或不典型增生的全国诊疗模式与生育结局

National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
PubMed 文献 · Am J Obstet Gynecol · 2019-05-22

基于美国Truven Marketscan保险理赔数据库,纳入2000至2014年诊断的≤45岁子宫内膜癌或不典型增生患者4007例,描述其诊疗模式与生育结局。多数(79.6%)接受标准手术治疗;初始孕激素治疗者中48.5%后续切除子宫。仅孕激素治疗者活产率为11.6%,使用辅助生育服务与活产可能性更高相关(OR 5.9)。

要点

  • 初始孕激素治疗比例随观察期显著上升,2014年至少初始接受孕激素治疗者占24.9%(P < .001)。
  • 仅孕激素治疗的421例中,92例(21.8%)共131次妊娠,49次活产,活产率11.6%。
  • 孕激素治疗者使用辅助生育服务与活产可能性更高相关(OR 5.9,95%CI 3.4-10.1,P < .0001)。

核心结论

  • 子宫内膜癌或不典型增生患者接受保留生育功能治疗的人数随时间增加,但诊断后活产的比例相对较小。

研究设计与样本

  • 基于美国Truven Marketscan商业保险理赔数据库的队列研究,纳入2000至2014年诊断的≤45岁子宫内膜癌或不典型增生患者4007例。

主要发现

  • 4007例中3189例(79.6%)接受标准手术治疗;818例初始接受孕激素治疗,其中397例(48.5%)后续行子宫切除术,421例(51.5%)未行子宫切除术。
  • 孕激素治疗组中位年龄低于标准手术组(36岁 vs 41岁,P < .001)。
  • 仅孕激素治疗的421例中,92例(21.8%;92/421)共发生131次妊娠,49次活产,活产率11.6%。
  • 孕激素治疗后行子宫切除术的397例中,25例(6.3%;25/397)共发生34次妊娠,13次活产。
  • 多因素分析显示,较年轻、诊断为不典型增生而非子宫内膜癌、以及研究期间较晚诊断均与接受孕激素治疗的可能性更高相关(P < .0001)。

关键数值与推荐

  • 孕激素治疗者中15.5%使用了某种形式的辅助生育服务。
  • 诊断后发生任何妊娠事件的患者中54%使用了某种生育治疗;诊断后活产的患者中50%接受了生育治疗。
  • 诊断后至活产的中位时间为756天(四分位距525-1077天)。
  • 孕激素治疗者若使用辅助生育服务,活产可能性更高(OR 5.9;95%CI 3.4-10.1;P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although it is uncommon, the incidence of endometrial cancer and atypical hyperplasia among reproductive-aged women is increasing. The fertility outcomes in this population are not well described. OBJECTIVE: We aim to describe the patterns of care and fertility outcomes of reproductive-aged women with endometrial cancer or atypical hyperplasia. MATERIALS AND METHODS: A cohort of women aged ≤45 years with endometrial cancer or atypical hyperplasia diagnosed in 2000 to 2014 were identified in Truven Marketscan, an insurance claims database of commercially insured patients in the United States. Treatment information, including use of progestin therapy, hysterectomy, and assisted fertility services, was identified and collected using a combination of Common Procedural Terminology codes, International Statistical Classification of Diseases and Related Health Problems codes, and National Drug Codes. Pregnancy events were identified from claims data using a similar technique. Patients were categorized as receiving progestin therapy alone, progestin therapy followed by hysterectomy, or standard surgical management with hysterectomy alone. Multivariable logistic regression was performed to assess factors associated with receiving fertility-sparing treatment. RESULTS: A total of 4007 reproductive-aged patients diagnosed with endometrial cancer or atypical hyperplasia were identified. The majority of these patients (n = 3189; 79.6%) received standard surgical management. Of the 818 patients treated initially with progestins, 397 (48.5%) subsequently underwent hysterectomy, whereas 421 (51.5%) did not. Patients treated with progestin therapy had a lower median age than those who received standard surgical management (median age, 36 vs 41 years; P < .001). The proportion of patients receiving progestin therapy increased significantly over the observation period, with 24.9% treated at least initially with progestin therapy in 2014 (P < .001). Multivariable analysis shows that younger age, a diagnosis of atypical hyperplasia diagnosis rather than endometrial cancer, and diagnosis later in the study period were all associated with a greater likelihood of receiving progestin therapy (P < .0001). Among the 421 patients who received progestin therapy alone, 92 patients (21.8%; 92/421) had 131 pregnancies, including 49 live births for a live birth rate of 11.6%. Among the 397 patients treated with progestin therapy followed by hysterectomy, 25 patients (6.3%; 25/397) had 34 pregnancies with 13 live births. The median age of patients who experienced a live birth following diagnosis during the study period was 36 years (interquartile range, 33-38). The use of some form of assisted fertility services was observed in 15.5% patients who were treated with progestin therapy. Among patients who experienced any pregnancy event following diagnosis, 54% of patients used some form of fertility treatment. For patients who experienced a live birth following diagnosis, 50% of patients received fertility treatment. Median time to live birth following diagnosis was 756 days (interquartile range, 525-1077). Patients treated with progestin therapy were more likely to experience a live birth if they had used assisted fertility services (odds ratio, 5.9; 95% confidence interval, 3.4-10.1; P < .0001). CONCLUSION: The number of patients who received fertility-sparing treatment for endometrial cancer or atypical hyperplasia increased over time. However, the proportion of women who experience a live birth following these diagnoses is relatively small.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019. PMID: 31128110. doi:10.1016/j.ajog.2019.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。